HONG KONG, May 29, 2026 – (ACN Newswire) – Driven by national industrial policy support and the comprehensive upgrading of public health needs, China’s biopharmaceutical industry has entered a new stage of high-quality and rapid growth. Autoimmune and allergic diseases are prevalent chronic conditions requiring long-term intervention…
Read More
